Edgewise Grants 72,000 Options at $32.46 Strike to Four New Hires
On March 31, 2026, Edgewise Therapeutics granted inducement stock options for 72,000 common shares to four new non-executive employees under its 2024 Inducement Equity Incentive Plan. Each option has a $32.46 exercise price matching the grant-date close and vests 25% after one year then monthly over 36 months.
1. Inducement Grant Details
On March 31, 2026, Edgewise Therapeutics issued inducement stock options to four non-executive employees under its 2024 Inducement Equity Incentive Plan, covering 72,000 shares of common stock. These grants were approved as material inducements to attract and retain talent in compliance with Nasdaq Listing Rule 5635(c)(4).
2. Vesting and Exercise Terms
Each option carries a $32.46 per share exercise price, equal to the closing market price on the grant date. Options vest 25% on the one-year anniversary of each employee’s start date and then 1/48th monthly thereafter, contingent on continued service.
3. Strategic Implications
These inducement grants align new hires’ incentives with the company’s clinical development milestones, supporting late-stage programs such as Sevasemten in muscular dystrophies and Phase 2 trials of EDG-7500 in hypertrophic cardiomyopathy. The awards reflect investment in critical talent while introducing potential incremental dilution.